Cardiol Therapeutics Inc.
NASDAQ:CRDLDrug Manufacturers - Specialty & Generic
-$0.01 today
- Market cap
- $114.64M
- Beta
- 0.80
- P/E (TTM)
- -4.5
- EPS (TTM)
- -$0.33
Volume 0.31M
Average 0.68M
CRDL Interest Income
Income earned on cash, deposits, and investments held by the company.
Cardiol Therapeutics Inc.NASDAQ: CRDL
Interest Income · Q1 FY2026 · quarter ended Mar 2026
Interest income declines year over year
Q1 FY2026 interest income of CA$201.24K fell 18.9% year over year, ahead of the -36.2% change in trailing-twelve-month interest income. Sequentially, it rose 14.9% from the prior quarter. Over 3 fiscal years it compounded at -16.3% a year.
Context
- Interest income increased in 1 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of -18.9% holds above the trailing-twelve-month pace of -36.2%.
Sources:Income StatementText generated from reported figures; not investment advice.
Interest Income history
CAD · from the income statement
- Latest · FY2025
- 726.4K CAD
- Year-over-year change
- -39.1%
- 4-year CAGR
- +61.8%
| Period | Period end | Interest Income | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 726.4K | -39.1% |
| FY2024 | 2024-12-31 | 1.19M | -41.5% |
| FY2023 | 2023-12-31 | 2.04M | +64.7% |
| FY2022 | 2022-12-31 | 1.24M | +1067.6% |
| FY2021 | 2021-12-31 | 106K | — |
Interest Income vs competitors
How CRDL compares with its peers on the latest reported figures
- Peers report in different currencies, so interest income is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of -36.2% is the 4th highest of 9, against a peer median of -45.5%.
- Over three fiscal years its annual growth of -16.3% compares with a peer median of +17.9%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
IMAImageneBio Inc | LTM Mar 2026 | $6.06M USD | -9.2% | -1.8% | — |
| LTM Mar 2026 | $2.41M USD | -25.2% | — | 2.4% | |
| FY2025 | $2.27M USD | -49.1% | +13.2% | 3543.8% | |
| LTM Mar 2026 | €1.62M EUR | -41.9% | +42.8% | 5520.1% | |
| LTM Mar 2026 | $1.55M USD | +466.3% | +187.6% | 1472.4% | |
| LTM Mar 2026 | $960K USD | -52.3% | +10.4% | 6.3% | |
| LTM Mar 2026 | CA$679.37K CAD | -36.2% | -16.3% | — | |
| LTM Mar 2026 | $0 USD | — | — | — | |
| LTM Jun 2025 | ₪0 ILS | -100.0% | +22.6% | 0.0% | |
KLRSKalaris Therapeutics Inc | LTM Mar 2026 | $0 USD | -100.0% | — | — |
| Peer median (excluding CRDL) | — | -45.5% | +17.9% | 739.3% | |
Competitors are the stored peer set for CRDL. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 62.27K | 0 | 0 | 0 | 0 |
| Cost of Revenue | 174.26K | 162.23K | 187.38K | 0 | 0 |
| Gross Profit | (112K) | (162.23K) | (187.38K) | 0 | 0 |
| Gross Margin | -179.9% | — | — | — | — |
| Research & Development | 8.59M | 13.99M | 10.73M | 14.01M | 14.02M |
| Selling, General & Admin | 21.86M | 16.34M | 11.55M | 25.89M | 20.2M |
| Operating Expenses | 30.46M | 30.33M | 22.29M | 40.28M | 34.32M |
| Depreciation & Amortization | 174.26K | 162.23K | 187.38K | 162.11K | 101.98K |
| EBITDA | (24.84M) | (22.66M) | (21.04M) | (36.52M) | (33.72M) |
| EBITDA Margin | -39891.0% | — | — | — | — |
| Operating Income | (30.57M) | (30.49M) | (22.47M) | (40.28M) | (34.32M) |
| Operating Margin | -49092.4% | — | — | — | — |
| Interest Income | 106K | 1.24M | 2.04M | 1.19M | 726.4K |
| Interest Expense | 0 | 0 | 0 | 0 | 0 |
| Other Income / Expenses | 5.56M | 7.68M | 1.25M | 3.6M | 497.42K |
| Income Before Tax | (25.01M) | (22.82M) | (21.22M) | (36.68M) | (33.82M) |
| Pre-Tax Margin | -40170.9% | — | — | — | — |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (25.01M) | (22.82M) | (21.22M) | (36.68M) | (33.82M) |
| Net Margin | -40170.9% | — | — | — | — |
| EPS (Basic) | (0.73) | (0.49) | (0.44) | (0.51) | (0.39) |
| EPS (Diluted) | (0.73) | (0.49) | (0.44) | (0.51) | (0.39) |
| Weighted Avg Shares | 43.22M | 62.51M | 64.46M | 71.57M | 86.99M |
| Weighted Avg Shares (Diluted) | 43.22M | 62.51M | 64.46M | 71.57M | 86.99M |
Cardiol Therapeutics Inc.
NASDAQ:CRDL
Intrinsic Alpha fair value
Locked
Current Price
$0.95
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.